Jeffrey Sivik

649 total citations
24 papers, 488 citations indexed

About

Jeffrey Sivik is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Jeffrey Sivik has authored 24 papers receiving a total of 488 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in Jeffrey Sivik's work include CAR-T cell therapy research (5 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Jeffrey Sivik is often cited by papers focused on CAR-T cell therapy research (5 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Jeffrey Sivik collaborates with scholars based in United States, Myanmar and Australia. Jeffrey Sivik's co-authors include Joseph J. Drabick, Todd D. Schell, Vernon M. Chinchilli, Nicole M Agostino, Junjia Zhu, Christopher J. Lynch, Ying Zhang, Kathleen M. Kokolus, Elizabeth A. Repasky and Giampaolo Talamo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jeffrey Sivik

21 papers receiving 481 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey Sivik United States	11	206	147	102	88	75	24	488
N. Gombakis Greece	15	73 0.4×	162 1.1×	26 0.3×	133 1.5×	24 0.3×	40	577
Hadj Benzerdjeb France	6	233 1.1×	84 0.6×	39 0.4×	104 1.2×	137 1.8×	6	852
Paul Basciano United States	11	115 0.6×	96 0.7×	42 0.4×	189 2.1×	108 1.4×	26	523
M. Demichele United States	10	159 0.8×	203 1.4×	30 0.3×	46 0.5×	17 0.2×	11	482
A. Dimitrakopoulos Greece	14	105 0.5×	139 0.9×	23 0.2×	18 0.2×	113 1.5×	30	658
Shiro Seto Japan	13	130 0.6×	215 1.5×	55 0.5×	13 0.1×	58 0.8×	24	586
Mariangela Sottili Italy	15	140 0.7×	147 1.0×	34 0.3×	11 0.1×	135 1.8×	29	547
Niamh Bermingham Ireland	10	139 0.7×	88 0.6×	12 0.1×	33 0.4×	107 1.4×	25	425
Matthew Rosebraugh United States	9	81 0.4×	31 0.2×	19 0.2×	79 0.9×	69 0.9×	21	513
Alexia Buzzonetti Italy	14	231 1.1×	116 0.8×	13 0.1×	45 0.5×	280 3.7×	30	615

Countries citing papers authored by Jeffrey Sivik

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Sivik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Sivik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Sivik more than expected).

Fields of papers citing papers by Jeffrey Sivik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Sivik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Sivik. The network helps show where Jeffrey Sivik may publish in the future.

Co-authorship network of co-authors of Jeffrey Sivik

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Sivik. A scholar is included among the top collaborators of Jeffrey Sivik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Sivik. Jeffrey Sivik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhu, Junjia, Ahmad Ozair, Jeffrey Sivik, et al.. (2025). A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy. Clinical Cancer Research. 31(15). 3276–3284.

Ssentongo, Paddy, et al.. (2025). Dose-dependent impact of tixagevimab–cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals. Scientific Reports. 15(1). 17578–17578.

Inoue, Yoshitaka, Hong Zheng, Kevin Rakszawski, et al.. (2025). Safety and feasibility of intermediate-dose post-transplant cyclophosphamide for graft-versus-host disease prophylaxis. Annals of Hematology. 104(12). 6451–6462.

Sivik, Jeffrey, Erik Lehman, Kevin Rakszawski, et al.. (2024). The addition of doxycycline to fluoroquinolones for bacterial prophylaxis in autologous stem cell transplantation for multiple myeloma. Transplant Infectious Disease. 26(2). e14241–e14241. 1 indexed citations

Sivik, Jeffrey, et al.. (2024). Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma. Annals of Plastic Surgery. 92(4S). S129–S131. 2 indexed citations

Winer, Arthur, Crystal S. Denlinger, Namrata Vijayvergia, et al.. (2020). First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 20(1). e43–e52. 3 indexed citations

Jia, Bei, Kevin Rakszawski, David F. Claxton, et al.. (2019). Eomes+T-betlow CD8+ T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia. Cancer Research. 79(7). 1635–1645. 48 indexed citations

Liao, Jason, et al.. (2018). Characteristics of pulmonary complications in non-Hodgkin’s lymphoma patients treated with rituximab-containing chemotherapy and impact on survival. Annals of Hematology. 97(12). 2373–2380. 10 indexed citations

Brennan, Matthew, et al.. (2018). Target wise and pound foolish: A simple technique to evaluate the trade-off between clinical benefit and economic burden of monoclonal antibodies. Journal of Cancer Policy. 18. 11–19. 1 indexed citations

10.

Mackley, Heath B., Jason Liu, Junjia Zhu, et al.. (2017). Improved infield response rates and overall survival in patients with metastatic melanoma receiving higher biological equivalent doses of radiation with ipilimumab. Journal of Radiation Oncology. 6(2). 215–223. 3 indexed citations

11.

Schell, Todd D., Jeremy S. Haley, Rogerio I. Neves, et al.. (2015). Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biology & Therapy. 16(5). 662–670. 21 indexed citations

12.

Talamo, Giampaolo, et al.. (2014). Bortezomib-induced acute pancreatitis: Case report and review of the literature. Journal of Oncology Pharmacy Practice. 22(2). 332–334. 11 indexed citations

13.

Kline, C. Leah B., Junjia Zhu, Harold A. Harvey, et al.. (2013). Personalized Dosing via Pharmacokinetic Monitoring of 5-Fluorouracil Might Reduce Toxicity in Early- or Late-Stage Colorectal Cancer Patients Treated With Infusional 5–Fluorouracil-Based Chemotherapy Regimens. Clinical Colorectal Cancer. 13(2). 119–126. 34 indexed citations

14.

Rakszawski, Kevin, Nathan G. Dolloff, Jeffrey Sivik, et al.. (2011). High-dose melphalan on day 2 versus 1 before autologous stem cell transplantation for multiple myeloma.. Journal of Clinical Oncology. 29(15_suppl). 6545–6545. 1 indexed citations

15.

Kline, C. Leah B., et al.. (2011). Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. Cancer Biology & Therapy. 12(7). 557–568. 18 indexed citations

16.

Agostino, Nicole M, et al.. (2010). Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. Journal of Oncology Pharmacy Practice. 17(3). 197–202. 129 indexed citations

17.

Agostino, Nicole M, et al.. (2010). Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice.. Journal of Clinical Oncology. 28(15_suppl). 4623–4623. 17 indexed citations

18.

Talamo, Giampaolo, David F. Claxton, David W. Dougherty, et al.. (2009). BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma. Bone Marrow Transplantation. 44(3). 157–161. 13 indexed citations

19.

Lancet, Jeffrey E., et al.. (2008). Safety, Feasibility, and Cost-Effectiveness with Outpatient Administration of High-Dose Cytarabine Consolidation in Acute Myeloid Leukemia. Blood. 112(11). 2405–2405. 4 indexed citations

20.

Sivik, Jeffrey, et al.. (2008). Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up. Journal of Oncology Pharmacy Practice. 14(4). 189–193. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact